STX213

STX213 is an orally active, second-generation **steroid sulfatase (STS) inhibitor** developed for the treatment of hormone-dependent cancers, including breast and endometrial cancers. It is a D-ring modified steroid-like compound with potent inhibitory activity (IC50 of 0.5 nM) against STS, an enzyme that regulates the conversion of steroid sulfates into active estrogens, thereby reducing estrogenic stimulation of tumors. Preclinical studies in both cell and animal models have shown that STX213 completely inhibits liver and tumor STS activity, reduces plasma estradiol levels, and significantly inhibits the growth of hormone-dependent tumors. Compared to the first-generation compound STX64, STX213 offers enhanced pharmacokinetics and a longer duration of action, maintaining efficacy even with less frequent dosing[1][3][5][7].

Other names

STX213STX-213STX 213